Arrowstreet Capital, Limited Partnership Akebia Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $65,725 - $359,700	-27,500 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$6.67 - $13.58 $183,425 - $373,450	27,500 New	27,500 $373,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $447,715 - $879,051	-109,199 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $590,766 - $953,307	109,199 New	109,199 $894,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $480,375 - $595,350	-52,500 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$9.53 - $15.68 $500,324 - $823,200	52,500 New	52,500 $500,000
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $1.72 Million - $2.37 Million	-121,089 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $1.58 Million - $2.38 Million	121,089	121,089 $2.38 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.